Ring1a protects against colitis through regulating mucosal immune system and colonic microbial ecology

Area of Science:

• Immunology
• Microbiology
• Genetics

Background:

• Inflammatory bowel disease (IBD) is a chronic immune disorder with complex, poorly understood origins involving genetics, immunity, and the gut microbiome.
• Identifying novel genetic factors influencing IBD pathogenesis is crucial for understanding disease mechanisms and developing targeted therapies.

Purpose of the Study:

• To investigate the role of the novel gene Ring1a in the development and progression of colitis.
• To elucidate the impact of Ring1a deficiency on the intestinal immune system and gut microbiota.
• To explore potential therapeutic strategies for colitis associated with Ring1a deficiency.

Main Methods:

• Utilized mouse models with Ring1a deficiency (Ring1aKO) and wild-type (WT) mice.
• Induced colitis using dextran sodium sulfate (DSS).
• Analyzed changes in the gut microbiota composition, immune responses (e.g., IgA levels), and disease severity.
• Administered metronidazole to assess its therapeutic effect in Ring1aKO mice.

Main Results:

• Ring1a deficiency exacerbated DSS-induced colitis, indicating its protective role in intestinal immunity.
• Ring1a deficiency led to a gut microbiota shift towards the Prevotella genus, which was transmissible and worsened colitis.
• Reduced IgA levels were observed in Ring1aKO mice, potentially linking microbiota alterations to immune dysfunction.
• Metronidazole treatment ameliorated colitis in Ring1aKO mice, likely by reducing Prevotella abundance.

Conclusions:

• Ring1a is identified as a novel candidate risk gene for colitis, regulating mucosal immunity and intestinal microbiota.
• Ring1a deficiency promotes a pathogenic gut microbial environment dominated by Prevotella, contributing to colitis severity.
• Metronidazole shows promise as a therapeutic agent for managing Prevotella-associated colitis in the context of Ring1a deficiency.